The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Combination Therapy using Co-encapsulated Resveratrol and Paclitaxel in Liposomes for Drug Resistance Reversal in Breast Cancer Cells in vivo
Open accessAbstract
Multidrug resistance (MDR) is a major impediment to cancer treatment. A promising strategy for treating MDR is the joint delivery of combined anticancer agents to tumor cells in a single nanocarrier. Here, for the first time, Resveratrol (Res) was co-encapsulated with paclitaxel (PTX) in a PEGylated liposome to construct a carrier-delivered form of combination therapy for drug-resistant tumors. The composite liposome had an average diameter of 50 nm with encapsulated efficiencies of above 50%. The studies demonstrated that the composite liposome could generate potent cytotoxicity against the drug-resistant MCF-7/Adr tumor cells in vitro and enhance the bioavailability and the tumor-retention of the drugs in vivo. Moreover, systemic therapy with the composite liposome effectively inhibited drug-resistant tumor in mice (p < 0.01), without any notable increase in the toxicity. These results suggested that the co-delivery of Res and a cytotoxic agent in a nanocarrier may potentially improve the treatment of drug-resistant tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Cited by
Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance
Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00193 · Cited by 1,451
Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment
García-Pinel, B., Porras-Alcalá, C., Ortega-Rodríguez, A., Sarabia, F., Prados, J., Melguizo, C., & López-Romero, J. M. (2019) · Nanomaterials · doi:10.3390/nano9040638 · Cited by 527
Nanomedicine review: clinical developments in liposomal applications
Beltrán-Gracia, E., López-Camacho, A., Higuera-Ciapara, I., Velázquez-Fernández, J. B., & Vallejo-Cardona, A. A. (2019) · Cancer Nanotechnology · doi:10.1186/s12645-019-0055-y · Cited by 513
PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application
Grossen, P., Witzigmann, D., Sieber, S., & Huwyler, J. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.05.028 · Cited by 496
Natural product-based nanoformulations for cancer therapy: Opportunities and challenges
Kashyap, D., Tuli, H. S., Yerer, M. B., Sharma, A., Sak, K., Srivastava, S., Pandey, A., Garg, V. K., Sethi, G., & Bishayee, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.014 · Cited by 390
A Compressive Review about Taxol®: History and Future Challenges
Gallego-Jara, J., Lozano-Terol, G., Sola-Martínez, R. A., Cánovas-Díaz, M., & de Diego Puente, T. (2020) · Molecules · doi:10.3390/molecules25245986 · Cited by 344
Liposome-based drug co-delivery systems in cancer cells
Zununi Vahed, S., Salehi, R., Davaran, S., & Sharifi, S. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2016.11.073 · Cited by 307
Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma
Jhaveri, A., Deshpande, P., Pattni, B., & Torchilin, V. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.03.006 · Cited by 294
Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them
Ramos, A., Sadeghi, S., & Tabatabaeian, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179451 · Cited by 289
Li, B., Shao, H., Gao, L., Li, H., Sheng, H., & Zhu, L. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2094498 · Cited by 289
Gao, Q., Feng, J., Liu, W., Wen, C., Wu, Y., Liao, Q., Zou, L., Sui, X., Xie, T., Zhang, J., et al. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114445 · Cited by 267
Lipid based nanocarriers: a translational perspective
Mishra, D. K., Shandilya, R., & Mishra, P. K. (2018) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2018.05.021 · Cited by 258
Therapeutic strategies to overcome taxane resistance in cancer
Das, T., Anand, U., Pandey, S. K., Ashby, C. R., Assaraf, Y. G., Chen, Z.-S., & Dey, A. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100754 · Cited by 253
Physicochemical characterization of drug nanocarriers
Berbel Manaia, E., Paiva Abuçafy, M., Chiari-Andréo, B. G., Lallo Silva, B., Oshiro-Júnior, J. A., & Chiavacci, L. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s133832 · Cited by 207
Cancer stem cells-emanated therapy resistance: Implications for liposomal drug delivery systems
Dianat-Moghadam, H., Heidarifard, M., Jahanban-Esfahlan, R., Panahi, Y., Hamishehkar, H., Pouremamali, F., Rahbarghazi, R., & Nouri, M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.043 · Cited by 140
Miguel, C. A., Noya-Riobó, M. V., Mazzone, G. L., Villar, M. J., & Coronel, M. F. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105188 · Cited by 70
Metadata
- Authors
- Meng, J., Guo, F., Xu, H., Liang, W., Wang, C., & Yang, X.-D.
- Venue
- Scientific Reports
- Published
- 2016-03-07
- Volume
- 6
- Issue
- 1
- Pages
- 22390-22390
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2299956717
- Cited by
- 236
- References
- 1
- FWCI
- 8.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.